<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392193</url>
  </required_header>
  <id_info>
    <org_study_id>18-009485</org_study_id>
    <nct_id>NCT04392193</nct_id>
  </id_info>
  <brief_title>Proton Particle Therapy for Cardiac Arrhythmia</brief_title>
  <official_title>Proton Particle Therapy for Cardiac Arrhythmia Extracorporeal Energy Source Ablation of Cardiac Tissue: A First Stage Early Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Douglas L. Packer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are gathering information on the safety and effectiveness of proton radiation&#xD;
      therapy in reducing the number of ventricular tachycardia (VT) episodes in subjects who&#xD;
      continue to experience VT despite treatment with an implantable cardioverter defibrillator&#xD;
      (ICD) and undergoing a previous catheter ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proton therapy has been approved by the U.S. Food and Drug Administration (FDA) for cancer&#xD;
      patients, including tumors in the heart, but not for treating heart rhythm disorders. The use&#xD;
      of proton radiation therapy to treat heart rhythm disorders including VT and ventricular&#xD;
      fibrillation (VF) is new and investigational; however, the FDA has approved proton therapy to&#xD;
      treat abnormal rhythm disorders for this study. The development of a proton radiation therapy&#xD;
      approach could be of substantial value in providing alternative therapy to either drug&#xD;
      therapy or catheter-based ablation. With appropriate development, this therapy may be&#xD;
      successful in the primary or secondary elimination of arrhythmias.&#xD;
&#xD;
      Participants will be followed at 1 and 2 weeks, 1, 3, 6, 12 and 24-month intervals following&#xD;
      treatment throughout the trial.&#xD;
&#xD;
      Participant involvement will last approximately two years from the time of the proton&#xD;
      radiation therapy procedure or until the last subject enrolled completes a 24 month&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of subject deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantable Cardioverter Defibrillator (ICD) Shocks</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of recurrent ICD shocks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent Ventricular Tachycardia (VT)</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of recurrent VT requiring repetitive antitachycardia pacing (ATP) device therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Arrest</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of cardiac arrests</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cardiac Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Proton Particle Therapy for Cardiac Arrhythmia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Particle Therapy</intervention_name>
    <description>Proton therapy will be delivered in a single fraction using the Probeat-V system</description>
    <arm_group_label>Proton Particle Therapy for Cardiac Arrhythmia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior myocardial infarction or non-ischemic disease resulting in myocardial&#xD;
             dysfunction&#xD;
&#xD;
          -  A left ventricular ejection fraction (EF) &lt;50%&#xD;
&#xD;
          -  An implanted ICD device as secondary prevention for monomorphic VT/VF. This includes&#xD;
             patients who receive a device for primary prevention and then have recurrent sustained&#xD;
             monomorphic VT or VT&#xD;
&#xD;
          -  Have failed a prior catheter-based ablation for VT/VF after device implantation or&#xD;
             have a contraindication to repeat ablation and and have failed reasonable drug options&#xD;
             over the 3 months prior to consideration of particle therapy&#xD;
&#xD;
          -  Repeat ablation from an epicardial venue in the absence of prior cardiac surgery, or&#xD;
             where such an ablation if felt to be inappropriate in the view of the primary&#xD;
             investigator&#xD;
&#xD;
          -  Electrocardiographic documentation of 2 additional episodes of recurrent, sustained&#xD;
             monomorphic ventricular tachycardia (MMVT) and/or pre-ventricular contraction (PVC)&#xD;
             induced VT or VF that are terminated by ATP or ICD shocks by device interrogation over&#xD;
             the past 3 months, since the sentinel ablation (see criteria #4).&#xD;
&#xD;
          -  Age â‰¤ 80 yrs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  VT in the absence of cardiomyopathy&#xD;
&#xD;
          -  Reversible causes of VT including thyroid disorders, acute alcohol intoxication,&#xD;
             recent major surgical procedures, trauma, or VT clearly produced by recurrent ischemia&#xD;
&#xD;
          -  Multiple (e.g. &gt;3) clinical VT morphologies, that are thought to originate from widely&#xD;
             disparate right ventricular (RV) or left ventricular (LV) areas.&#xD;
&#xD;
          -  Recent cardiac events including myocardial infarction (MI), percutaneous coronary&#xD;
             intervention (PCI), or valve or bypass surgery in the preceding 3 months, or&#xD;
             anticipated in the next 3 months&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy &gt; Class IV&#xD;
&#xD;
          -  Progressive Class IV angina or Class IV congestive heart failure (CHF) (including past&#xD;
             or planned heart transplantation)&#xD;
&#xD;
          -  Heritable arrhythmias or increased risk for torsade de pointes with class I or III&#xD;
             drugs&#xD;
&#xD;
          -  Prior surgical interventions for VT such as an encircling ventriculotomy procedure&#xD;
&#xD;
          -  Contraindication to appropriate anti-coagulation therapy after ablation&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Prior therapeutic radiation therapy to the left chest that would preclude safe&#xD;
             ablation of the cardiac target in the judgment of the radiation oncologist&#xD;
&#xD;
          -  Medical conditions limiting expected survival to &lt;1 year&#xD;
&#xD;
          -  Women of childbearing potential (unless post-menopausal or surgically sterile)&#xD;
&#xD;
          -  Participation in any other clinical mortality trial (Participation in other&#xD;
             non-mortality trials should be reviewed with the clinical trial management center)&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas L Packer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristi H Monahan, RN</last_name>
    <phone>507-255-6676</phone>
    <email>monahan.kristi@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacqueline R Crowson</last_name>
    <phone>507-255-6263</phone>
    <email>crowson.jacqueline@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Monahan, RN</last_name>
      <phone>507-255-6676</phone>
      <email>monahan.kristi@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Douglas L. Packer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Cardiac Ablation</keyword>
  <keyword>Proton Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

